mAb Biosimilars Market 2016-2020

Overview of the mAb biosimilars market

Extensive research carried out by the analysts at Technavio has shown that the global mAb biosimilars market is anticipated to witness tremendous growth and will post a staggering CAGR of more than 57% over the forecast period. The increasing need for cost-effective treatment is one of the major factors driving this market’s growth. Biosimilars are available at a 10% to 30% discount, leading to their increased adoption. For instance, Inflectra was one of the first biosimilar products to receive marketing authorization in the US market, and it costs around 25% less than the original product. As biosimilar products are positioned as a cost-effective treatment option, its market is likely to grow significantly over the next four years.

One of the recent trends impelling the growth of this market is the rising number of strategic collaborations. Vendors in the market are forming strategic alliances to increase their market share, for example, in 2011, Amgen and Watson Pharmaceuticals reached an agreement to develop and commercialize biosimilar treatments for cancer. As a part of this agreement, Amgen is expected to develop and manufacture biosimilars with Watson and provide marketing and financial support for the products launched.

Competitive landscape and key vendors

The global mAb biosimilars market is characterized by the presence of several well-established vendors. The vendors focus on selling their products to commercial laboratories and hospitals whose numbers have increased in the recent past and will increase in future due to greater healthcare spending and improved infrastructure in a bid to expand their reach in the market.

 Key vendors in this market are -

• Biocon
• Celltrion
• Dr. Reddy's Laboratories
• Hospira

Other prominent vendors in the market include 3SBio, Accord Healthcare, AET Biotech, Allergan, Alvartis Pharma, Amega Biotech, Amgen, Apotex, Aspen, AstraZeneca, Aurobindo Pharma, Baxter, Bharat Serums, Bio Sidus, Biogen, Bionovis, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, Boston Oncology, Cipla, Coherus Biosciences, Daiichi Sankyo, Emcure Pharmaceuticals, Gedeon Richter, GeneScience Pharmaceuticals, GSK, Hetero Drugs, iBio, Intas Pharmaceuticals, JCR Pharmaceuticals, LG Lifesciences, Lonza, Merck, Mitsubishi Tanabe Pharma, Momenta Pharmaceuticals, Mylan, Natco Pharma, Novartis, Pfenex, Pfizer, Ranbaxy Laboratories, Roche Holding, Samsung Biologics, Sanofi, and Synthon.

Segmentation by application and analysis of the mAb biosimilars market

• Chronic and autoimmune diseases
• Oncology

During 2015, the chronic and autoimmune diseases segment was the highest revenue contributor and is expected to the lead the market in the coming years. The growth of this segment is attributed to a rise in the geriatric population, the improved standards of healthcare facilities, and the availability of sophisticated treatment options. The rise in the older population has consequently led to an increase in the incidence of diseases such as chronic arthritis, osteoarthritis, diabetic neuropathy, cancer, and autoimmune diseases, which, in turn, will propel this sector’s growth over the predicted period.

Geographical segmentation and analysis of the mAb biosimilars market

• Asia
• Europe
• ROW

In terms of geography, Europe dominated the global mAb market and is expected to continue its dominance until 2020. The market will witness significant growth in countries such as the UK, Germany, Spain, France, and Italy. The introduction of new biosimilars will boost this market’s growth in the region. Also, well-defined and flexible regulatory guidelines are some of the major factors contributing to this market’s growth in Europe.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global mAb biosimilars market?
• What are the key market trends impacting the growth of the global mAb biosimilars market?
• What are the challenges to market growth?
• Who are the key vendors in the global mAb biosimilars market?
• What are the market opportunities and threats faced by the vendors in the global mAb biosimilars market?
• What are the trending factors influencing the market shares of the Asia, Europe, and ROW?
• What are the key outcomes of the five forces analysis of the global mAb biosimilars market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Biosimilars Market 2016-2020
• Global Oncology Biosimilars Market 2016-2020
• Global Generic Drugs Market 2016-2020
• Global Breast Cancer Monoclonal Antibodies Market 2016-2020

Biosimilars can be termed as the follow-on versions of original biological medicines. These are developed after the patent protecting the original product has expired or is set to expire. mAb, i.e., biosimilar monoclonal antibodies are complex proteins that recognize and counterbalance foreign bodies, such as bacteria and viruses. mAb is used by the immune system and is a part of the biosimilar family. They are also used in the treatment of life-threatening diseases like cancer and other illness such as rheumatoid arthritis. In simple terms, mAbs could be seen as “shields” used by the immune system to fight the aforementioned diseases.

The report, global mAb biosimilars market, is part of Technavio’s healthcare and life sciences research portfolio. This portfolio provides a comprehensive market analysis along with the market share, market sizing, and market segmentations covering areas such as cardiovascular and metabolic disorders, central nervous system, oncology, medical imaging, life science research tools, and vaccines. These market research reports provide a perspective on the various market opportunities and market threats along with the key trends that would influence the market growth during the forecast period. It presents insights into the changing competitive landscape and a detailed profiling and market analysis of the vendors. Also covered in the research are the key regions or countries that would have an impact on the market during the assessment years.